The anfiandrogen drugs, medroxyprogesterone acetate (MPA) and cyproterone acetate (CPA) have been available as part of a treatment package for transgressors for almost 30 years. Uncontrolled and controlled studies on approximately !,000 offenders (e.g., pedophiles, rapists; exhibitionists) indicate the agents to be equipotent and approximately equivalent in decreasing tensions, fantasies, preoccupation, and sexual actingout and in cases studied longitudinally over several years, recidivism has been reduced (Cooper 1986). MPA and CPA are not effective in every case, however, (Dickey |992; Rousseau et al 1990) and paradoxical effects have been reported in which arousal has increased despite the expected marked reduction in testosterone levels (Cooper 1987). Additionally, CPA and MPA are steroids and may be associated with a number of adverse consequences, including: fatigue, depression, hypoglycemia, gynecomastia, weight gain, breast nodules, possible thromboemboiic p~enomena, and adrenal suppression. MPA is believed to be possibly carcinogenic in beagle dogs. (Rosenfield et al 1983). The recent development of LHRH (luteinizing hormone-releasing hormone) agonists and experience gained during their use in the treatment of prostatic carcinoma, have suggested that they might be helpful in reducing libido in some offenders. Moreover, synthetic LHRH agonists, like native LHRH are peptides, therefore, they are inherently safer than steroids, and are to be preferred for this reason. Moreover, a few case studies (Dickey 1992; Rousseau et al 1990) have pointed to superior efficacy in